Gliomas, especially glioblastoma (GBM), express tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) that can be targeted by vaccines. The goal is to trigger a T cell–mediated immune response against tumor cells without harming healthy brain tissue.